[
  {
    "ts": null,
    "headline": "Billionaire Asness Sold Cisco Systems (CSCO) and Bought Eli Lilly and Company (LLY)",
    "summary": "We recently compiled a list of the 10 Stocks Dominating a Billionaire Quant’s Investment Strategy. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks that are dominating a billionaire quant’s investment strategy. AQR Capital Management is a global investment management firm, founded by […]",
    "url": "https://finnhub.io/api/news?id=800b029aa6a2f112e8d588d4bf7d411e7483a20e9d57a8209d0cffe92ac0c2ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733607579,
      "headline": "Billionaire Asness Sold Cisco Systems (CSCO) and Bought Eli Lilly and Company (LLY)",
      "id": 131852127,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Stocks Dominating a Billionaire Quant’s Investment Strategy. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks that are dominating a billionaire quant’s investment strategy. AQR Capital Management is a global investment management firm, founded by […]",
      "url": "https://finnhub.io/api/news?id=800b029aa6a2f112e8d588d4bf7d411e7483a20e9d57a8209d0cffe92ac0c2ed"
    }
  },
  {
    "ts": null,
    "headline": "3 No-Brainer Growth Stocks to Buy in December",
    "summary": "It's what most investors want more than anything else from their stocks.  Three Motley Fool contributors think they've identified no-brainer growth stocks in the healthcare sector to buy in December.  Here's why they picked Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).",
    "url": "https://finnhub.io/api/news?id=bf69b9783857da469220b530a38db69cfa372df39b90c78dfcfb2e58245cca69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733571960,
      "headline": "3 No-Brainer Growth Stocks to Buy in December",
      "id": 131843967,
      "image": "https://g.foolcdn.com/editorial/images/800044/excited-investor-looks-at-financial-charts-on-computer.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It's what most investors want more than anything else from their stocks.  Three Motley Fool contributors think they've identified no-brainer growth stocks in the healthcare sector to buy in December.  Here's why they picked Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).",
      "url": "https://finnhub.io/api/news?id=bf69b9783857da469220b530a38db69cfa372df39b90c78dfcfb2e58245cca69"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Eli Lilly and Company (LLY) Among the Best Dividend Stocks to Invest In Now?",
    "summary": "We recently compiled a list of the 10 Dividend Knights that Beat The Market Last 3 Years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks that beat the market in the last 3 years. The broader market has been performing strongly […]",
    "url": "https://finnhub.io/api/news?id=5f86c373daaa05f3e674d53797a19390847c0bf1e17604c2ff3c3e657dac1a9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733561559,
      "headline": "Why Is Eli Lilly and Company (LLY) Among the Best Dividend Stocks to Invest In Now?",
      "id": 131852130,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Dividend Knights that Beat The Market Last 3 Years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks that beat the market in the last 3 years. The broader market has been performing strongly […]",
      "url": "https://finnhub.io/api/news?id=5f86c373daaa05f3e674d53797a19390847c0bf1e17604c2ff3c3e657dac1a9d"
    }
  },
  {
    "ts": null,
    "headline": "Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.",
    "summary": "Eli Lilly (NYSE: LLY) has produced a wide variety of treatments for various illnesses throughout its 145-year history.  Lilly makes tirzepatide, which is approved for type 2 diabetes under the name Mounjaro and for weight control under the name Zepbound (though doctors have also prescribed Mounjaro for patients trying to lose weight).  The pharma company won approval for the former back in 2022 and then for the latter about a year ago.",
    "url": "https://finnhub.io/api/news?id=16ae8d1da9d0462f7423de751be2ad0f5d8e88c8690694f6a9bb7b706328882d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733559300,
      "headline": "Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.",
      "id": 131839865,
      "image": "https://g.foolcdn.com/editorial/images/800023/gettyimages-1070239362.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) has produced a wide variety of treatments for various illnesses throughout its 145-year history.  Lilly makes tirzepatide, which is approved for type 2 diabetes under the name Mounjaro and for weight control under the name Zepbound (though doctors have also prescribed Mounjaro for patients trying to lose weight).  The pharma company won approval for the former back in 2022 and then for the latter about a year ago.",
      "url": "https://finnhub.io/api/news?id=16ae8d1da9d0462f7423de751be2ad0f5d8e88c8690694f6a9bb7b706328882d"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 8",
    "summary": "Stay updated on dividend activity with a weekly summary for Dividend Champions, Contenders, and Challengers, including changes and upcoming dates.",
    "url": "https://finnhub.io/api/news?id=ae7a5308efcb593f9f10b20c5b0d90e3e3cc49fe6db9655cd120b24d9f556902",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733531855,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 8",
      "id": 131834837,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Stay updated on dividend activity with a weekly summary for Dividend Champions, Contenders, and Challengers, including changes and upcoming dates.",
      "url": "https://finnhub.io/api/news?id=ae7a5308efcb593f9f10b20c5b0d90e3e3cc49fe6db9655cd120b24d9f556902"
    }
  }
]